logo
Boston Dynamics Led a Robot Revolution. Now Its Machines Are Teaching Themselves New Tricks

Boston Dynamics Led a Robot Revolution. Now Its Machines Are Teaching Themselves New Tricks

WIRED26-02-2025

Feb 26, 2025 1:42 PM Boston Dynamics founder Marc Raibert says reinforcement learning is helping his creations gain more independence. Photo-Illustration:Marc Raibert, the founder and chairman of Boston Dynamics, gave the world a menagerie of two- and four-legged machines capable of jaw-dropping parkour, infectious dance routines, and industrious shelf stacking.
Raibert is now looking to lead a revolution in robot intelligence as well as acrobatics. And he says that recent advances in machine learning have accelerated his robots' ability to learn how to perform difficult moves without human help. 'The hope is that we'll be able to produce lots of behavior without having to handcraft everything that robots do,' Raibert told me recently.
Boston Dynamics might have pioneered legged robots, but it's now part of a crowded pack of companies offering robot dogs and humanoids. Only this week, a startup called Figure showed off a new humanoid called Helix, which can apparently unload groceries. Another company, x1, showed off a muscly-looking humanoid called NEO Gamma doing chores around the home. A third, Apptronik, said it plans to scale up the manufacturing of his humanoid, called Apollo. Demos can be misleading, though. Also, few companies disclose how much their humanoids cost, and it is unclear how many of them really expect to sell them as home helpers.
The real test for these robots will be how much they can do independent of human programming and direct control. And that will depend on advancements like the ones Raibert is touting. Last November I wrote about efforts to create entirely new kinds of models for controlling robots. If that work starts to bear fruit we may see humanoids and quadrupeds advance more rapidly.
Boston Dynamics' Spot RL Sim in action. Credit: Boston Dynamics
Boston Dynamics sells a four-legged robot called Spot that is used on oil rigs, construction sites, and other places where wheels struggle with the terrain. The company also makes a humanoid called Atlas for research. Raibert says Boston Dynamics used an artificial intelligence technique called reinforcement learning to upgrade Spot's ability to run, so that it moves three times faster. The same method is also helping Atlas walk more confidently, Raibert says.
Reinforcement learning is a decades-old way of having a computer learn to do something through experimentation combined with positive or negative feedback. It came to the fore last decade when Google DeepMind showed it could produce algorithms capable of superhuman strategy and gameplay. More recently, AI engineers have used the technique to get large language models to behave themselves.
Raibert says highly accurate new simulations have sped up what can be an arduous learning process by allowing robots to practice their moves in silico. 'You don't have to get as much physical behavior from the robot [to generate] good performance,' he says.
Several academic groups have published work that shows how reinforcement learning can be used to improve legged locomotion. A team at UC Berkeley used the approach to train a humanoid to walk around their campus. Another group at ETH Zurich is using the method to guide quadrupeds across treacherous ground.
Boston Dynamics has been building legged robots for decades, based on Raibert's pioneering insights on how animals balance dynamically using the kind of low-level control provided by their nervous system. As nimble footed as the company's machines are, however, more advanced behaviors, including dancing, doing parkour, and simply navigating around a room, normally require either careful programming or some kind of human remote control.
In 2024 Raibert founded the Robotics and AI (RAI) Institute to explore ways of increasing the intelligence of legged and other robots so that they can do more on their own. While we wait for robots to actually learn how to do the dishes, AI should make them less accident prone. 'You break fewer robots when you actually come to run the thing on the physical machine,' says Al Rizzi, chief technology officer at the RAI Institute.
What do you make of the many humanoid robots now being demoed? What kinds of tasks do you think they should do? Write to us at hello@wired.com or comment below.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Spotify (SPOT) Stock Dips While Market Gains: Key Facts
Spotify (SPOT) Stock Dips While Market Gains: Key Facts

Yahoo

time6 hours ago

  • Yahoo

Spotify (SPOT) Stock Dips While Market Gains: Key Facts

In the latest market close, Spotify (SPOT) reached $699.11, with a -1.85% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 0.09%. The music-streaming service operator's stock has climbed by 9.87% in the past month, falling short of the Computer and Technology sector's gain of 11.17% and outpacing the S&P 500's gain of 7.21%. Analysts and investors alike will be keeping a close eye on the performance of Spotify in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $2.27, marking a 58.74% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $4.79 billion, indicating a 16.93% growth compared to the corresponding quarter of the prior year. SPOT's full-year Zacks Consensus Estimates are calling for earnings of $9.72 per share and revenue of $19.94 billion. These results would represent year-over-year changes of +63.36% and +17.6%, respectively. It is also important to note the recent changes to analyst estimates for Spotify. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.63% downward. Spotify is currently sporting a Zacks Rank of #3 (Hold). Valuation is also important, so investors should note that Spotify has a Forward P/E ratio of 73.27 right now. This indicates a premium in contrast to its industry's Forward P/E of 29.83. We can additionally observe that SPOT currently boasts a PEG ratio of 1.78. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Internet - Software industry stood at 2.39 at the close of the market yesterday. The Internet - Software industry is part of the Computer and Technology sector. This industry currently has a Zacks Industry Rank of 57, which puts it in the top 24% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow SPOT in the coming trading sessions, be sure to utilize Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Spotify Technology (SPOT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

MediPharm Labs' Founder-CEO Pat McCutcheon Throws his Support behind Apollo Capital as Dissident
MediPharm Labs' Founder-CEO Pat McCutcheon Throws his Support behind Apollo Capital as Dissident

Yahoo

time7 hours ago

  • Yahoo

MediPharm Labs' Founder-CEO Pat McCutcheon Throws his Support behind Apollo Capital as Dissident

McCutcheon Agrees with Apollo that Urgent Change is Needed, including Complete Turnover at the Board Level after Years of Value-Destruction Apollo Capital Announces Filing of Circular Addendum to Reflect McCutcheon's EndorsementTORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporation ("Apollo Capital"), one of MediPharm Lab Corp's (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm', or the 'Company') largest investors, is very pleased to announce that Pat McCutcheon, a founder, former CEO, director and Chairman of MediPharm, has joined Apollo Capital as a co-dissident in its battle to bring integrity, transparency and prosperity back to MediPharm's long-suffering shareholders. Pat McCutcheon stated: 'I have been observing Apollo's activist campaign from the sidelines, and I can no longer just sit by and watch. I still feel a deep responsibility to the Company, its employees and the shareholders who have invested millions into the vision of MediPharm being the global leader in medical cannabis and cannabis derived pharmaceutical products. Over the past three years, the share price has collapsed while the senior management team has been paid over $10,000,000, a compensation program that should never have been approved by the independent Directors. Management has failed to capitalize on the medical cannabis opportunity and taken the Company away from its founding vision by entering the recreational market, taking on dilutive M&A transactions and recently announcing a return to cultivating cannabis. This is not the MediPharm investors have supported. I have gotten to know Regan McGee & his team of proposed directors. The directors have a broad range of relevant experience including medical cannabis experience, turn-around experience, and extensive capital markets experience. Regan has demonstrated himself to be a skilled investor who has been successful in both start-ups and turn-around projects. He's also overcome great personal adversity, showing that he never backs down from a fight. In terms of the negative statements from MediPharm about Regan, the ones that I have been able to independently verify have turned out to be simply fabrications that appear to be part of MediPharm's campaign to discredit and defame Regan. I believe the attacks on Regan & his business record are not factual and more importantly hide the real issues that shareholders should be considering such as compensation, dilution & the share price. On each of these fronts, I believe the Apollo directors are a better choice than the directors put forward by the current Board. We need to focus on the real issues – who is going to drive the stock price higher. Apollo only makes money when the stock price goes up, as all the shareholders do together. This is why I support the Apollo team. I'm asking shareholders to vote GOLD at this year's AGM. We do not have time to wait.' Apollo notes that its business model with MediPharm is highly aligned with shareholders. As an activist investor, it looks to make investments in poorly managed companies where new governance and management can work to improve the share price for Apollo and all other investors. Apollo's business model is to buy stock in target companies and work with frustrated shareholders to secure the majority of votes needed to replace board members and executives with ones focused on share value growth. Apollo does not 'take over' or otherwise control its target companies, rather it appoints directors who recognize their legal fiduciary duty to act in the best interests of all common shareholders. Regan McGee of Apollo Capital commented: 'We are immensely proud to welcome Pat McCutcheon as a co-dissident. Pat is responsible for helping to build MediPharm into an absolute powerhouse in the cannabis industry, and I can only imagine how difficult it has been for him to watch the Company he loves so much be mismanaged virtually to the point of insolvency. Pat and I want exactly the same thing – to restore value to MediPharm shareholders and to usher in a new era of profitability, good governance and most importantly, accountability. We both believe that if we all come together and take urgent action, the future for the MediPharm will be bright.' In connection with the addition of Mr. McCutcheon as a 'dissident' within the meaning of applicable corporate laws, an addendum dated June 4, 2025 (the 'Addendum') to the dissident information circular dated May 15, 2025 (the 'Circular') has been filed on under MediPharm's profile. Shareholders are encouraged to read the Circular, as supplemented and amended by the Addendum. Apollo Capital's strategic five-pillar plan for MediPharm has been made available in detail at With shareholder support, we can turn MediPharm around and transform it into the world's leading medical cannabis company. Apollo Capital urges shareholders to vote for change by voting the GOLD CARD by June 12, 2025. Shareholders are urged NOT to sign or return the green proxy cards sent by the Company. Contacts For Shareholders:Carson ProxyNorth American Toll-Free Phone: 1-800-530-5189Local or Text Message: 416-751-2066 (collect calls accepted)E: info@ For Media:media@ This solicitation is being made by and on behalf of the Concerned Shareholder, who, as of the date of this Circular, beneficially owns or controls, directly and indirectly through its wholly-owned subsidiary, Nobul Technologies Inc., 12,491,500 common shares of the Company ('Common Shares'), representing approximately 3% of the total Common Shares issued and outstanding, and not by the management of the Company ('Management'). Legal Disclosures Information in Support of Public Broadcast Exemption under Canadian Law In connection with the annual general and special meeting (the 'Annual Meeting') of shareholders of MediPharm, Apollo Capital has filed an amended and restated dissident information circular dated May 15, 2025 (the 'Circular'), as amended and supplemented by an addendum to the Circular subsequently filed by Apollo Capital and Patrick McCutcheon (together, the 'Concerned Stakeholder') dated June 4, 2025 (the 'Addendum' and together with the Circular, the 'Amended Circular'), each in compliance with applicable corporate and securities laws. The Concerned Stakeholder has provided in, or incorporated by reference into, this press release the disclosure required under section 9.2(4) of NI 51-102 – Continuous Disclosure Obligations ('NI 51-102') and the corresponding exemption under the Business Corporations Act (Ontario), and has filed the Amended Circular, available under MediPharm's profile on SEDAR+ at The Amended Circular contains disclosure prescribed by applicable corporate law and disclosure required under section 9.2(6) of NI 51-102 in respect of the Concerned Stakeholder's director nominees, in accordance with corporate and securities laws applicable to public broadcast solicitations. The Amended Circular is hereby incorporated by reference into this press release and is available under MediPharm's profile on SEDAR+ at The registered office of the Company is 151 John Street, Barrie, Ontario, Canada L4N 2L1. SHAREHOLDERS OF MEDIPHARM ARE URGED TO READ THE AMENDED CIRCULAR CAREFULLY BECAUSE IT CONTAINS IMPORTANT INFORMATION. Investors and shareholders are able to obtain free copies of the Amended Circular and any amendments or supplements thereto and further proxy circulars at no charge under MediPharm's profile on SEDAR+ at In addition, shareholders are also able to obtain free copies of the Amended Circular and other relevant documents by contacting the Concerned Stakeholder's proxy solicitor, Carson Proxy Advisors Ltd. ('Carson Proxy') at 1-800-530-5189, local (collect outside North America): 416-751-2066 or by email at info@ Proxies may be revoked in accordance with subsection 110(4) of the Business Corporations Act (Ontario) by a registered shareholder of Company shares: (a) by completing and signing a valid proxy bearing a later date and returning it in accordance with the instructions contained in the accompanying form of proxy; (b) by depositing an instrument in writing executed by the shareholder or by the shareholder's attorney authorized in writing; (c) by transmitting by telephonic or electronic means a revocation that is signed by electronic signature in accordance with applicable law, as the case may be: (i) at the registered office of the Company at any time up to and including the last business day preceding the day the Annual Meeting or any adjournment or postponement of the Annual Meeting is to be held, or (ii) with the chair of the Annual Meeting on the day of the Annual Meeting or any adjournment or postponement of the Annual Meeting; or (d) in any other manner permitted by law. In addition, proxies may be revoked by a non-registered holder of Company shares at any time by written notice to the intermediary in accordance with the instructions given to the non-registered holder by its intermediary. It should be noted that revocation of proxies or voting instructions by a non-registered holder can take several days or even longer to complete and, accordingly, any such revocation should be completed well in advance of the deadline prescribed in the form of proxy or voting instruction form to ensure it is given effect in respect of the Annual Meeting. The costs incurred in the preparation and mailing of any circular or proxy solicitation by the Concerned Stakeholder and any other participants named herein will be borne directly and indirectly by Apollo Capital. However, to the extent permitted under applicable law, Apollo Capital intends to seek reimbursement from the Company of all expenses incurred in connection with the solicitation of proxies for the election of its director nominees at the Annual Meeting. This press release and any solicitation made by the Concerned Stakeholder is, or will be, as applicable, made by such parties, and not by or on behalf of the management of the Company. Proxies may be solicited by proxy circular, mail, telephone, email or other electronic means, as well as by newspaper or other media advertising and in person by managers, directors, officers and employees of the Concerned Stakeholder who will not be specifically remunerated therefor. In addition, the Concerned Stakeholder may solicit proxies by way of public broadcast, including press release, speech or publication and any other manner permitted under applicable Canadian laws, and may engage the services of one or more agents and authorize other persons to assist it in soliciting proxies on their behalf. Apollo Capital has entered into an agreement with Carson Proxy for solicitation and advisory services in connection with the solicitation of proxies by the Concerned Stakeholder for the Annual Meeting, for which Carson Proxy will receive a fee from Apollo Capital not to exceed $250,000, together with reimbursement for reasonable and out-of-pocket expenses. Apollo Capital has also engaged Gasthalter & Co. LP ('G&Co') to act as communications consultant to provide the Concerned Stakeholder with certain communications, public relations and related services, for which G&Co will receive, from Apollo Capital, a minimum fee of US$75,000 in addition to a performance fee of US$250,000 in the event that the Concerned Stakeholder's nominees make up a majority of the board of directors of MediPharm (the 'Board') following the Annual Meeting, plus excess fees, related costs and expenses. No member of the Concerned Stakeholder nor any of their respective associates or affiliates has or has had any material interest, direct or indirect, in any transaction since the beginning of the Company's last completed financial year or in any proposed transaction that has materially affected or will or would materially affect the Company or any of the Company's affiliates. No member of the Concerned Stakeholder nor any of their respective associates or affiliates has any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Annual Meeting, other than setting the number of directors and the election of directors to the Board. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward‐looking statements. All statements contained in this filing that are not clearly historical in nature or that necessarily depend on future events are forward‐looking, and the words 'anticipate,' 'believe,' 'expect,' 'estimate,' 'plan,' and similar expressions are generally intended to identify forward‐looking statements. These statements are based on current expectations of the Concerned Stakeholder and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate. All forward-looking statements contained herein are made only as of the date hereof and the Concerned Stakeholder disclaims any intention or obligation to update or revise any such forward-looking statements to reflect events or circumstances that subsequently occur, or of which the Concerned Stakeholder hereafter becomes aware, except as required by applicable law. Hashtags: #ShareholderActivism #CorporateGovernance #InvestorProtection #Investor Alert #Investor Fraud #FinancialRegulation #CorporateCrime #FinancialCrime #HomelandSecurity #DHS #OpioidCrisis #OpioidEpidemic #OpioidLitigation #OpioidVictims #BMO #DEA #ONDCPSign in to access your portfolio

Apollo eyes $100 billion Germany investment as private capital swerves U.S. turmoil for Europe
Apollo eyes $100 billion Germany investment as private capital swerves U.S. turmoil for Europe

CNBC

time8 hours ago

  • CNBC

Apollo eyes $100 billion Germany investment as private capital swerves U.S. turmoil for Europe

MEGA, or "Make Europe Great Again," was a hot topic at this year's biggest private markets event last week. The about-turn in sentiment toward the continent was illustrated no better than when the boss of industry juggernaut Apollo said he saw the opportunity to put $100 billion "in the ground" in Germany over the next decade. "I think many investors in Europe see the opportunity, and many investors in U.S. see the opportunity right now in Europe. They see it across the private equity ecosystem. They also see it across the credit ecosystem," Apollo Global Management President Jim Zelter said during a keynote interview. As well as direct lending, Zelter said he saw big opportunity in investment-grade commercial and residential real estate, highlighting domestic housing shortages in Spain and the U.K. On Germany, Zelter said the $100 billion investment figure would be hard to match anywhere in the world outside of the U.S., and that the country had "woken up Europe to focus on financing industry, military and a variety of other critical industries." His comments will be welcomed by Germany's new government, which has called for private capital to help meet its infrastructure needs alongside public funding. Sentiment began to significantly shift around the sluggish German economy in March, when lawmakers approved alterations to longstanding debt restrictions to allow the establishment of a $500 billion fund for defense, infrastructure and climate-related projects. At the start of May, center-right, pro-business politician Friedrich Merz — who has served on the boards of BlackRock Germany, EY Germany and the Deutsche Börse — was confirmed as Germany's new chancellor, ending months of political uncertainty. Merz met with U.S. President Donald Trump last week , achieving some diplomatic wins in his attempt to strengthen ties between the countries and urge further support for Ukraine. Europe bulls, U.S. nerves Joana Rocha Scaff, head of European private equity at Neuberger Berman, told CNBC that many investors had started the year overweight the U.S. and intending to extend their allocations, expecting deregulation and a boost to economic growth, only to be abruptly stymied by Trump's tariff policies. "In the midst of this turbulence and noise in the U.S., we have seen capital be redirected towards Europe," she said, with her own investment firm "actively investing in the market" alongside its core general partners, or GPs. Neuberger Berman's active market investments deploy around $4 billion of capital on a direct basis a year, she said. So far this year, Europe has accounted for around 65% of direct investment activity, up from around 20-30% of global market activity on a typical year, she noted. Those investments have been broad, she continued but generally oriented around developed parts of Europe, energy security and transition, defense, digitalization and industrial assets. Private equity's enthusiasm toward Europe has also been reflected in public markets. Germany's blue chip DAX index is up around 22% this year, versus around 1% for the Dow Jones Industrial Average . Europe's Aerospace and Defense Index is up nearly 50%, while a tracker index of the long-buzzy Magnificent 7 U.S. tech giants is down 2%. For retail investors seeking opportunities in the space, JPMorgan recently named its top European stock picks for the next year — and they include defense names Rheinmetall and Babcock International , IT firms SAP and Dassault Systems , and infrastructure picks Alstom , Heidelberg Materials and Saint-Gobain . There are also new ways for retail investors to track private credit returns through exchange-traded funds — though experts warn private markets are complex and come with significant risks . Earlier this year, State Street and Apollo Global Management launched the SPDR SSGA Apollo IG Public & Private Credit ETF (PRIV) exchange-traded fund (ETF), which aims to have at least 80% of its assets in investment-grade private and public debt securities.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store